- Home
- SBFM vs XRTX Comparison
SBFM vs XRTX Comparison
Compare SBFM & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- XRTX
- Stock Information
- Founded
- SBFM 2006
- XRTX 2011
- Country
- SBFM United States
- XRTX Canada
- Employees
- SBFM N/A
- XRTX N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- XRTX Pharmaceuticals and Biotechnology
- Sector
- SBFM Health Care
- XRTX Health Care
- Exchange
- SBFM Nasdaq
- XRTX Nasdaq
- Market Cap
- SBFM 4.6M
- XRTX 4.2M
- IPO Year
- SBFM N/A
- XRTX N/A
- Fundamental
- Price
- SBFM $1.51
- XRTX $0.92
- Analyst Decision
- SBFM Strong Buy
- XRTX
- Analyst Count
- SBFM 1
- XRTX 0
- Target Price
- SBFM $15.00
- XRTX N/A
- AVG Volume (30 Days)
- SBFM 104.9K
- XRTX 34.6K
- Earning Date
- SBFM 05-15-2025
- XRTX 05-16-2025
- Dividend Yield
- SBFM N/A
- XRTX N/A
- EPS Growth
- SBFM N/A
- XRTX N/A
- EPS
- SBFM N/A
- XRTX N/A
- Revenue
- SBFM $36,234,578.00
- XRTX N/A
- Revenue This Year
- SBFM $192.48
- XRTX N/A
- Revenue Next Year
- SBFM N/A
- XRTX N/A
- P/E Ratio
- SBFM N/A
- XRTX N/A
- Revenue Growth
- SBFM 35.51
- XRTX N/A
- 52 Week Low
- SBFM $1.17
- XRTX $0.80
- 52 Week High
- SBFM $11.39
- XRTX $2.98
- Technical
- Relative Strength Index (RSI)
- SBFM 54.20
- XRTX 43.86
- Support Level
- SBFM $1.37
- XRTX $0.88
- Resistance Level
- SBFM $1.56
- XRTX $0.97
- Average True Range (ATR)
- SBFM 0.08
- XRTX 0.06
- MACD
- SBFM 0.02
- XRTX -0.01
- Stochastic Oscillator
- SBFM 73.68
- XRTX 18.85
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.